PTC Therapeutics (NASDAQ:PTCT) CEO Sells $511,252.56 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew Klein sold 7,371 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $511,252.56. Following the completion of the transaction, the chief executive officer directly owned 387,082 shares in the company, valued at approximately $26,848,007.52. The trade was a 1.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $70.66 on Monday. The firm has a market cap of $5.85 billion, a price-to-earnings ratio of 9.13 and a beta of 0.48. The stock has a 50-day simple moving average of $74.91 and a 200-day simple moving average of $68.14. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company’s quarterly revenue was down 22.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.85) EPS. As a group, equities research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PTCT shares. Citigroup raised their target price on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Morgan Stanley reissued an “overweight” rating and set a $90.00 price objective on shares of PTC Therapeutics in a report on Thursday, January 8th. Wall Street Zen lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Barclays upgraded PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $68.00 to $119.00 in a report on Tuesday, January 27th. Finally, Bank of America reduced their price objective on shares of PTC Therapeutics from $97.00 to $93.00 and set a “buy” rating for the company in a research note on Friday. Ten equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $80.73.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Full-year product and royalty revenue topped guidance and Sephience (sepiapterin) showed strong early commercial uptake (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M). The company also ended 2025 with ~$1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
• Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but maintained a “buy” rating — an analyst endorsement that can temper downside and attract buyers despite the cut. Benzinga
• Neutral Sentiment: Earnings-call transcripts and analyst notes are available to parse management commentary and one‑time vs. structural drivers of the miss; these will be important for judging whether weakness is temporary or persistent. Earnings Call Transcript
• Negative Sentiment: Q4 results materially missed expectations: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — a large shortfall that directly pressured the stock. Zacks: Q4 miss
• Negative Sentiment: Management set FY‑2026 revenue guidance at $700M–$800M versus Street consensus near $974M — a notable downgrade that reduces near‑term upside and raises questions on commercial demand assumptions. PR Newswire: Guidance
• Negative Sentiment: Regulatory uncertainty increased after PTC withdrew a Translarna NDA, prompting fresh questions about that program’s prospects and potential contribution to future revenue. Yahoo: Translarna article
• Negative Sentiment: Significant insider selling occurred Feb. 17–18 (CEO, CFO, EVP, CAO and other insiders sold shares in multiple filings). While sales can be routine (taxes, diversification), clustered executive sales can be perceived negatively by the market. SEC Form 4 (example)

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Mcguire Capital Advisors Inc. bought a new stake in shares of PTC Therapeutics in the fourth quarter valued at approximately $397,000. Invesco Ltd. boosted its holdings in PTC Therapeutics by 38.7% in the 4th quarter. Invesco Ltd. now owns 434,285 shares of the biopharmaceutical company’s stock valued at $32,988,000 after purchasing an additional 121,228 shares during the period. Summit Global Investments bought a new stake in PTC Therapeutics in the 4th quarter valued at $242,000. State of Tennessee Department of Treasury acquired a new stake in PTC Therapeutics in the 4th quarter worth $2,465,000. Finally, Mackenzie Financial Corp increased its holdings in shares of PTC Therapeutics by 17.4% during the 4th quarter. Mackenzie Financial Corp now owns 236,909 shares of the biopharmaceutical company’s stock worth $18,015,000 after purchasing an additional 35,117 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.